Inhibikase Therapeutics (IKT) Total Non-Current Liabilities (2024 - 2026)
Inhibikase Therapeutics' (IKT) quarterly Total Non-Current Liabilities came in at $5.3 million in Q1 2026, up 29.08% year-on-year from $4.1 million in Q1 2025, and up 29.08% on a QoQ basis from $4.1 million in Q1 2025.
Inhibikase Therapeutics (IKT) Total Non-Current Liabilities (2024 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has 3 years of Total Non-Current Liabilities data on file, last reported at $5.3 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Inhibikase Therapeutics | 55.25 Mn | -115.12 Mn | - | 5.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.31 Mn |
| Mar 31, 2025 | 4.12 Mn |
| Mar 31, 2024 | 4.29 Mn |